Salvina Therapeutics

Allschwil, Switzerland

Salvina Therapeutics is developing novel antibodies targeting TNF to overcome efficacy barriers in inflammatory and autoimmune diseases.

$545K raised

Oct 2023

Grant

Biopharma Biotechnology Life Science

Top Investors

BaseLaunch

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Salvina Therapeutics

How much funding has Salvina Therapeutics raised?

Salvina Therapeutics has raised $545K in total funding. The most recent round was Grant. The last funding was announced in October 2023.

Who are Salvina Therapeutics's investors?

Salvina Therapeutics's investors include BaseLaunch.

Where is Salvina Therapeutics headquartered?

Salvina Therapeutics is headquartered in Allschwil, Switzerland.

What does Salvina Therapeutics do?

Salvina Therapeutics is developing novel antibodies targeting TNF to overcome efficacy barriers in inflammatory and autoimmune diseases.

What stage is Salvina Therapeutics at?

Salvina Therapeutics is at the Grant stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 2, 2023.

MLA

"Salvina Therapeutics — Funding & Investors." VCBacked, October 2, 2023, https://www.vcbacked.co/company/salvina-therapeutics. Accessed July 1, 2026.

APA

VCBacked. (2023). Salvina Therapeutics — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/salvina-therapeutics

Wikipedia (cite web)

{{cite web |title=Salvina Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/salvina-therapeutics |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 2, 2023.

Similar Companies in Biopharma

View all

Allterum Therapeutics

Living In Silico Inc.